United States: CMS Finalizes Medicare Part B Reimbursement Cut For 340B – What Does It Mean?

Last Updated: November 6 2017
Article by Ellyn Sternfield

On November 1, 2017, CMS announced that it is in fact cutting Medicare Part B reimbursement for 340B drugs to the tune of $1.6 billion. To be accurate, what CMS announced is its intent to finalize proposed rule changes to the Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Quality Reporting Program. As part of the rule changes, CMS will be implementing, with minor tweaks, the proposal it first announced last summer to significantly reduce Medicare Part B reimbursement for 340B drugs paid to hospitals and ambulatory surgical centers. The full text of the final rule with commentary is available now and will be published in the Federal Register on November 13th. The reimbursement reduction, and other changes relative to 340B, are scheduled to go into effect on January 1, 2018.

The rule only impacts Medicare Part B reimbursement for 340B, and no other government or private payor reimbursement. Still, the change will have major repercussions in the 340B world. When the proposed rule was first announced, I posted answers to a myriad of questions about the proposal and its potential impact on 340B covered entities. With the "rule" now in final form, I can revisit some of those questions and answers.

  1. What is the change to Medicare Part B Reimbursement for 340B drugs? Effective January 1, 2018, CMS will reduce Part B reimbursement for 340B drugs from Average Sales Price (ASP) plus 6% to ASP minus 22.5%.
  2. Does the change apply to all 340B covered entities? The mechanism for the change is a revision to the Outpatient Prospective (OPPS) and Ambulatory Surgical Center (ASC) Payment Systems, so the change only applies to entities that utilize those systems: generally hospitals, Community Mental Health Centers, and ASCs. However, there are three types of hospitals that receive OPPS payment adjustments: rural sole community hospitals, children's hospitals, and OPPS-exempt cancer hospitals These three types of hospitals are exempted from the reduction in Medicare Part B reimbursement and will still receive the ASP plus 6% reimbursement rate for Medicare Part B drugs.
  3. Does the change apply to all 340B drugs? The change applies to most, but not all, 340B drugs. While CMS considered multiple exceptions, only vaccines and drugs that are on transitional pass-through payment status (assigned status indicator "G") will be excluded from the Medicare Part B payment reduction. CMS did say that it is open to reconsidering additional exemptions in future years based on further data or information.
  4. How much will CMS save and what will CMS do with the savings? CMS believes that the reduction in Medicare Part B reimbursement will save it approximately $1.6 billion for calendar year 2018. But because the mechanism for the change is the OPPS and ASC adjustments, the change must be budget neutral. CMS states that it will "redistribute" the savings to the covered entities by increasing the conversion factor for non-drug items paid through the OPPS and ASC Payment Systems by 3.2%.
  5. Did CMS add requirements related to the use of modifiers in billing 340B drugs? In order to effectuate the payment adjustment as well as to collect data for future use, CMS is requiring impacted hospitals and facilities subject to the reduced reimbursement to add the modifier "JG" on the same claim line as the HCPCS code to identify any drug purchased through the 340B program. For rural sole community hospitals, children's hospitals, OPPS-exempt cancer hospitals, or any other hospital exempt from the payment reduction, they must also use a modifier "TB" on the claim line to identify any drugs purchased through the 340B program. This change is also effective January 1, 2018.
  6. Does CMS have legal authority to unilaterally implement these changes? This remains the key question. CMS asserts it has statutory authority under 42 U.S.C. 1395I(t)(14)(A)(iii)(II) to "adjust" hospital payments for outpatient drugs based on hospital acquisition cost data or, if the data is not available, by the average price for the drug "as calculated and adjusted by the Secretary." CMS asserts that multiple studies support the conclusion that ASP plus 6% far exceeds hospital acquisition cost for 340B drugs; moreover, given the confidentiality of 340B ceiling and subceiling prices, it lacks the data to determine an average price. Based on cited studies and the statutory authorities, CMS asserts it is authorized to make an "adjustment" and reduce payments for these drugs to more closely approximate what the entities paid to purchase the drugs. However, while CMS asserts it is appropriate to make this change through rulemaking, there continues to be no actual "rule" proposed by CMS as part of 42 CFR to effectuate the change.

So what happens next? While there might be some appeals to HRSA, HRSA is powerless to act on the proposed change.

As we know, Congress is considering changes to the 340B Program, and lobbying of Congress to halt the implementation of the rule is likely already underway. But as part of its commentary to the final rule, CMS focused on the benefit to Medicare beneficiaries in the form of reduced co-pays for 340B drugs – otherwise beneficiaries are paying 20% of a charge that far exceeds what the entity paid to purchase the product. Congress may not have the appetite to prevent those reduced co-pays from going into effect. That leaves the courts.

Several groups, including American Hospital Association, Association of American Medical Colleges, and America's Essential Hospitals, have already vowed to pursue litigation to prevent the rule from taking effect. Arguments will likely include whether CMS can meets its statutory obligation to "calculate" acquisition cost by citing others' studies, and whether CMS can legally make the change through "rule-making" without actually proposing a "rule."

So for 340B stakeholders, you may want to buckle your seatbelts folks – it is definitely going to be a bumpy ride.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Ellyn Sternfield
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions